Does the media prefer PRTC or OXB?

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of -1.32 indicating that Oxford Biomedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PRTC or SLN?

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to PRTC or AVCT?

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.00 beat PureTech Health's score of -1.32 indicating that Avacta Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PRTC or HZD?

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ARIX or PRTC?

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

PureTech Health (PRTC) Competitors

GBX 118.32 -2.68 (-2.22%)

As of 07:25 AM Eastern

Compare

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Biomedica?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.26	-£91.86M	-£46.00	N/A
Oxford Biomedica	£168.74M	3.28	-£143.51M	-£26.92	N/A

30.7% of PureTech Health shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PureTech Health has a beta of 0.771, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.092, suggesting that its share price is 9% more volatile than the broader market.

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Oxford Biomedica has a consensus target price of GBX 580.85, indicating a potential upside of 27.10%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts clearly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. Oxford Biomedica's average media sentiment score of 0.75 beat PureTech Health's score of -1.32 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oxford Biomedica beats PureTech Health on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.26	-£91.86M	-£46.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

In the previous week, PureTech Health had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat PureTech Health's score of -1.32 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Negative
Silence Therapeutics	Neutral

30.7% of PureTech Health shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher possible upside, research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PureTech Health beats Silence Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

PureTech Health (LON:PRTC) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

PureTech Health has a beta of 0.771, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

30.7% of PureTech Health shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 13.4% of PureTech Health shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Avacta Group has lower revenue, but higher earnings than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.26	-£91.86M	-£46.00	N/A
Avacta Group	£113K	3,111.66	-£30.08M	-£9.66	N/A

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 329.35%. Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 31.92%. Given PureTech Health's higher probable upside, research analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.00 beat PureTech Health's score of -1.32 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PureTech Health and Avacta Group tied by winning 7 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

PureTech Health (LON:PRTC) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, PureTech Health had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 beat PureTech Health's score of -1.32 indicating that Horizon Discovery Group plc (HZD.L) is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Negative
Horizon Discovery Group plc (HZD.L)	Neutral

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	62.26	-£91.86M	-£46.00	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

30.7% of PureTech Health shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

PureTech Health beats Horizon Discovery Group plc (HZD.L) on 7 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

PureTech Health has a consensus target price of GBX 508, indicating a potential upside of 329.35%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 30.7% of PureTech Health shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, meaning that its share price is 23% less volatile than the broader market.

Arix Bioscience has a net margin of 105.64% compared to PureTech Health's net margin of -2,355.32%. Arix Bioscience's return on equity of 6.41% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Arix Bioscience has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
PureTech Health	£4.66M	62.26	-£91.86M	-£46.00	N/A

In the previous week, PureTech Health had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 beat PureTech Health's score of -1.32 indicating that Arix Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Arix Bioscience	Neutral
PureTech Health	Negative

Summary

Arix Bioscience beats PureTech Health on 11 of the 15 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£290.09M	£3.90B	£7.25B	£2.91B
Dividend Yield	N/A	3.64%	2.53%	6.23%
P/E Ratio	-2.57	14.19	275.10	366.55
Price / Sales	62.26	1,393.24	688.88	90,280.05
Price / Cash	2.14	41.62	28.04	27.89
Price / Book	1.04	15.59	10.57	6.40
Net Income	-£91.86M	-£22.86M	£3.49B	£5.89B
7 Day Performance	-1.24%	0.72%	0.79%	1.35%
1 Month Performance	0.61%	-4.67%	-2.82%	0.29%
1 Year Performance	-5.65%	34.73%	16.67%	19.81%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	2.5214 of 5 stars	GBX 118.32 -2.2%	GBX 508 +329.4%	-0.4%	£290.09M	£4.66M	N/A	300	News Coverage
OXB Oxford Biomedica	2.9103 of 5 stars	GBX 460 +0.3%	GBX 580.85 +26.3%	-21.5%	£555.01M	£168.74M	N/A	891
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.7688 of 5 stars	GBX 77.35 +1.8%	GBX 99 +28.0%	+49.5%	£362.42M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does PureTech Health compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, AVCT, HZD, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Which has stronger valuation and earnings, PRTC or OXB?

Do institutionals & insiders believe in PRTC or OXB?

Which has more risk and volatility, PRTC or OXB?

Do analysts prefer PRTC or OXB?

Is PRTC or OXB more profitable?

Does the media prefer PRTC or OXB?

Summary

How does PureTech Health compare to Silence Therapeutics?

Is PRTC or SLN more profitable?

Which has stronger earnings and valuation, PRTC or SLN?

Does the media prefer PRTC or SLN?

Do insiders and institutionals have more ownership in PRTC or SLN?

Do analysts prefer PRTC or SLN?

Summary

How does PureTech Health compare to Avacta Group?

Which has more volatility & risk, PRTC or AVCT?

Do insiders and institutionals hold more shares of PRTC or AVCT?

Is PRTC or AVCT more profitable?

Which has better earnings & valuation, PRTC or AVCT?

Do analysts prefer PRTC or AVCT?

Does the media refer more to PRTC or AVCT?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Does the media refer more to PRTC or HZD?

Which has preferable earnings & valuation, PRTC or HZD?

Do institutionals and insiders have more ownership in PRTC or HZD?

Do analysts prefer PRTC or HZD?

Is PRTC or HZD more profitable?

Summary

How does PureTech Health compare to Arix Bioscience?

Do analysts recommend ARIX or PRTC?

Do institutionals & insiders believe in ARIX or PRTC?

Which has more volatility and risk, ARIX or PRTC?

Is ARIX or PRTC more profitable?

Which has better earnings and valuation, ARIX or PRTC?

Does the media prefer ARIX or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools